Serum lactate as a potential biomarker of non-glial brain tumors

2015 ◽  
Vol 22 (10) ◽  
pp. 1625-1627 ◽  
Author(s):  
Suparna Bharadwaj ◽  
Lashmi Venkatraghavan ◽  
Ramamani Mariappan ◽  
Julius Ebinu ◽  
Ying Meng ◽  
...  
Author(s):  
Y Meng ◽  
S Bharadwaj ◽  
J Ebinu ◽  
L Venkatraghavan ◽  
G Zadeh

Introduction: Serum lactate levels are useful indicators of illness severity such as sepsis. Previous investigations have shown that lactate is a potential biomarker for glioma malignancy; mechanism of which may be related to Warburg effect - accelerated lactate production when tumors uniquely undergo aerobic glycolysis. Our study reveals a correlation between serum lactate and meningioma WHO grade. We also observed a relationship between radiation effect on metastatic brain tumors and lactate levels. Methods: Data was collected from the charts of 14 patients with grade I meningiomas, 6 grade II meningiomas, and 9 metastatic brain tumors who underwent resection at our institution from 2013-2014. T test and ANCOVA were carried using R software controlling for base deficit. Results: The mean age was 53 years, with 75% females. There was a statistically significant change in intra- and post-operative lactate during meningioma resections, which had a strong positive correlation with grade (p<0.005). Interestingly, the lactate rise was not significant for metastatic brain tumors (p=0.13), but had a positive correlation with tumors that received pre-operative radiation (p<0.05). Conclusion: Lactate is a potential non-invasive biomarker for brain tumor malignancy, as demonstrated in gliomas and meningiomas. Identifying metabolic biomarkers and their relationship to tumor pathology is important to understanding disease processes and improving patient care.


2021 ◽  
Vol 11 ◽  
Author(s):  
Rashmi Rana ◽  
Kirti Chauhan ◽  
Poonam Gautam ◽  
Mahesh Kulkarni ◽  
Reema Banarjee ◽  
...  

Gliomas are the most common type of the malignant brain tumor, which arise from glial cells. They make up about 40% of all primary brain tumors and around 70% of all primary malignant brain tumors. They can occur anywhere in the central nervous system (CNS) and have a poor prognosis. The average survival of glioma patients is approximately 6–15 months with poor aspects of life. In this edge, identification of proteins secreted by cancer cells is of special interest because it may provide a better understanding of tumor progression and provide early diagnosis of the diseases. Extracellular vesicles (EVs) were isolated from pooled plasma of healthy controls (n=03) and patients with different grades of glioma (Grade I or II or III, n=03 each). Nanoparticle tracking analysis, western blot, and flow cytometry were performed to determine the size, morphology, the concentration of glioma-derived vesicles and EV marker, CD63. Further, iTRAQ-based LC-MS/MS analysis of EV protein was performed to determine the differential protein abundance in extracellular vesicles across different glioma grades. We further verified galectin-3 binding protein (LGALS3BP) by ELISA in individual blood plasma and plasma-derived vesicles from control and glioma patients (n=40 each). Analysis by Max Quant identified 123 proteins from the pooled patient exosomes, out of which 34, 21, and 14 proteins were found to be differentially abundant by more than 1.3-fold in the different grades of glioma grade I, pilocytic astrocytoma; grade II, diffuse astrocytoma; grade III, anaplastic astrocytoma, respectively, in comparison with the control samples. A total of seven proteins—namely, CRP, SAA2, SERPINA3, SAA1, C4A, LV211, and KV112—showed differential abundance in all the three grades. LGALS3BP was seen to be upregulated across the different grades, and ELISA analysis from individual blood plasma and plasma-derived extracellular vesicles confirmed the increased expression of LGALS3BP in glioma patients (p&lt;0.001). The present study provides LGALS3BP as a potential biomarker for early detection of glioma and improve survival outcome of the patient. The present study further provides the information of progression and monitoring the tumor grades (grade 1, grade II, grade III).


2015 ◽  
Vol 22 (1) ◽  
pp. 144-148 ◽  
Author(s):  
Ramamani Mariappan ◽  
Lashmi Venkatraghavan ◽  
Alenoush Vertanian ◽  
Sameer Agnihotri ◽  
Shalini Cynthia ◽  
...  

2014 ◽  
Vol 1842 (7) ◽  
pp. 1137-1143 ◽  
Author(s):  
Angela M. Amorini ◽  
Viviana Nociti ◽  
Axel Petzold ◽  
Claudio Gasperini ◽  
Esmeralda Quartuccio ◽  
...  

PROTEOMICS ◽  
2012 ◽  
Vol 12 (13) ◽  
pp. 2158-2166 ◽  
Author(s):  
Claudia Desiderio ◽  
Luca D'Angelo ◽  
Diana Valeria Rossetti ◽  
Federica Iavarone ◽  
Bruno Giardina ◽  
...  

2022 ◽  
Vol 12 ◽  
Author(s):  
Xin Chu ◽  
Chenyi Di ◽  
Panpan Chang ◽  
Lina Li ◽  
Zhe Feng ◽  
...  

ObjectiveTo date, there are no studies regarding the lactylation profile and its role in critically ill patients. Thus, we aimed to examine expression of histone H3 lysine 18 (H3K18) lactylation and its role in patients with septic shock.MethodsThirteen healthy volunteers and 35 critically ill patients from the Department of Surgical Intensive Care Medicine, Beijing Hospital were enrolled in our study. Baseline information and clinical outcomes were obtained prospectively. Lactylation levels of all proteins and H3K18 from peripheral blood mononuclear (PBMC) were determined by western blotting and serum levels of inflammatory cytokines by flow cytometry. Arginase-1 (Arg1) and Krüppel-like factor-4 (Klf4) mRNA expression was evaluated by quantitative real-time PCR (qRT-PCR).ResultsLactylation was found to be an all-protein post-translational modification and was detected in PBMCs from both healthy volunteers and critically ill patients, with a significantly higher relative density in shock patients (t=2.172, P=0.045). H3K18la was expressed in all subjects, including healthy volunteers, with the highest level in septic shock patients (compared with non-septic shock patients, critically ill without shock patients and healthy volunteers P=0.033, 0.000 and 0.000, respectively). Furthermore, H3K18la protein expression correlated positively with APACHE II scores, SOFA scores on day 1, ICU stay, mechanical ventilation time and serum lactate (ρ=0.42, 0.63, 0.39, 0.51 and 0.48, respectively, ρ=0.012, 0.000, 0.019, 0.003 and 0.003, respectively). When we matched patients with septic shock and with non-septic shock according to severity, we found higher H3K18la levels in the former group (t=-2.208, P =0.040). Moreover, H3K18la exhibited a close correlation with procalcitonin levels (ρ=0.71, P=0.010). Patients with high H3K18la expression showed higher IL-2, IL-5, IL-6, IL-8, IL-10, IL-17, IFN-α levels (ρ=0.33, 0.37, 0.62, 0.55, 0.65, 0.49 and 0.374 respectively, P=0.024, 0.011, 0.000, 0.000, 0.000 and 0.000 respectively). H3K18la expression also displayed a positive correlation with the level of Arg1 mRNA (ρ=0.561, P=0.005).ConclusionsLactylation is an all-protein post-translational modification occurring in both healthy subjects and critically ill patients. H3K18la may reflect the severity of critical illness and the presence of infection. H3K18la might mediate inflammatory cytokine expression and Arg1 overexpression and stimulate the anti-inflammatory function of macrophages in sepsis.


2021 ◽  
Vol 11 ◽  
Author(s):  
Frederic A. Vallejo ◽  
Steven Vanni ◽  
Regina M. Graham

Glioblastoma (GBM) remains one of the most lethal primary brain tumors in both adult and pediatric patients. Targeting tumor metabolism has emerged as a promising-targeted therapeutic strategy for GBM and characteristically resistant GBM stem-like cells (GSCs). Neoplastic cells, especially those with high proliferative potential such as GSCs, have been shown to upregulate UCP2 as a cytoprotective mechanism in response to chronic increased reactive oxygen species (ROS) exposure. This upregulation plays a central role in the induction of the highly glycolytic phenotype associated with many tumors. In addition to shifting metabolism away from oxidative phosphorylation, UCP2 has also been implicated in increased mitochondrial Ca2+ sequestration, apoptotic evasion, dampened immune response, and chemotherapeutic resistance. A query of the CGGA RNA-seq and the TCGA GBMLGG database demonstrated that UCP2 expression increases with increased WHO tumor-grade and is associated with much poorer prognosis across a cohort of brain tumors. UCP2 expression could potentially serve as a biomarker to stratify patients for adjunctive anti-tumor metabolic therapies, such as glycolytic inhibition alongside current standard of care, particularly in adult and pediatric gliomas. Additionally, because UCP2 correlates with tumor grade, monitoring serum protein levels in the future may allow clinicians a relatively minimally invasive marker to correlate with disease progression. Further investigation of UCP2’s role in metabolic reprogramming is warranted to fully appreciate its clinical translatability and utility.


2020 ◽  
Vol 48 (5) ◽  
pp. 2295-2305
Author(s):  
Jiawei Zhang ◽  
Dandan Li ◽  
Rui Zhang ◽  
Peng Gao ◽  
Rongxue Peng ◽  
...  

The role of miR-21 in the pathogenesis of various liver diseases, together with the possibility of detecting microRNA in the circulation, makes miR-21 a potential biomarker for noninvasive detection. In this review, we summarize the potential utility of extracellular miR-21 in the clinical management of hepatic disease patients and compared it with the current clinical practice. MiR-21 shows screening and prognostic value for liver cancer. In liver cirrhosis, miR-21 may serve as a biomarker for the differentiating diagnosis and prognosis. MiR-21 is also a potential biomarker for the severity of hepatitis. We elucidate the disease condition under which miR-21 testing can reach the expected performance. Though miR-21 is a key regulator of liver diseases, microRNAs coordinate with each other in the complex regulatory network. As a result, the performance of miR-21 is better when combined with other microRNAs or classical biomarkers under certain clinical circumstances.


Sign in / Sign up

Export Citation Format

Share Document